Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease
- Conditions
- COVID-19
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Apogenix GmbH
- Target Recruit Count
- 34
- Registration Number
- NCT05639192
- Locations
- 🇦🇹
Univeritätsklinik für Innere Medizin I, Wien, Austria
🇫🇷CHU Amiens - Site Sud, Centre de Recherche Clinique, Amiens, France
🇫🇷Dubois Hospital, Service de médecine intensive Réanimation, Brive-la-Gaillarde, France
APG101 in Myelodysplastic Syndrome
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Drug: Treatment with APG101Procedure: Bone marrow collectionProcedure: Blood drawings
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Apogenix GmbH
- Target Recruit Count
- 20
- Registration Number
- NCT01736436
- Locations
- 🇩🇪
Universitaetsklinik Heidelberg, Medizinische Klinik V, Haematologie, Onkologie & Rheumatologie, Heidelberg, Germany
🇩🇪Universitaetsmedizin Mannheim, III. Medizinische Klinik, Haematologie und Onkologie, Mannheim, Germany
APG101 in Glioblastoma
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2015-06-16
- Lead Sponsor
- Apogenix GmbH
- Target Recruit Count
- 84
- Registration Number
- NCT01071837
- Locations
- 🇦🇹
Medizinische Universität Graz, Universitätsklinik für Neurologie Landeskrankenhaus Graz, Graz, Austria
🇦🇹Universitätsklinik für Neurologie, Landeskrankenhaus Innsbruck, Innsbruck, Austria
🇦🇹Landesnervenklinik Wagner-Jauregg, Innere Medizin mit Neuroonkologie, Linz, Austria
News
Asunercept Shows Promise in Reducing Mortality and Accelerating Recovery in Severe COVID-19
A Phase 2 clinical trial reveals that asunercept, a FasL inhibitor, significantly accelerates recovery in patients with severe COVID-19, reducing the average recovery time from 13 to 8 days.